cblc137 and Neoplasms

cblc137 has been researched along with Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for cblc137 and Neoplasms

Article	Year
ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis. Nature, 2022, Volume: 606, Issue:7914 Only a small proportion of patients with cancer show lasting responses to immune checkpoint blockade (ICB)-based monotherapies. The RNA-editing enzyme ADAR1 is an emerging determinant of resistance to ICB therapy and prevents ICB responsiveness by repressing immunogenic double-stranded RNAs (dsRNAs), such as those arising from the dysregulated expression of endogenous retroviral elements (EREs) Topics: 3' Untranslated Regions; Adenosine Deaminase; Animals; Cancer-Associated Fibroblasts; Carbazoles; Humans; Immunotherapy; Interferons; Melanoma; Mice; Necroptosis; Neoplasms; RNA-Binding Proteins; RNA, Double-Stranded	2022

Article

Year

ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis.

Nature, 2022, Volume: 606, Issue:7914

Only a small proportion of patients with cancer show lasting responses to immune checkpoint blockade (ICB)-based monotherapies. The RNA-editing enzyme ADAR1 is an emerging determinant of resistance to ICB therapy and prevents ICB responsiveness by repressing immunogenic double-stranded RNAs (dsRNAs), such as those arising from the dysregulated expression of endogenous retroviral elements (EREs)

Topics: 3' Untranslated Regions; Adenosine Deaminase; Animals; Cancer-Associated Fibroblasts; Carbazoles; Humans; Immunotherapy; Interferons; Melanoma; Mice; Necroptosis; Neoplasms; RNA-Binding Proteins; RNA, Double-Stranded

2022